Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success Marina Elena CazzanigaRomano DanesiNetworkER+ Review Open access 07 May 2019 Pages: 483 - 494
Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer Michael Patrick LuxSarah BöhmeDiana Lüftner Review Open access 07 May 2019 Pages: 495 - 506
De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis Arif Ali AwanBrian HuttonMark Clemons Review 11 May 2019 Pages: 507 - 517
Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis Motahare PilevarzadehMehrbanoo AmirshahiAbbas Balouchi Review 13 May 2019 Pages: 519 - 533
Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis John SilberholzDimitris BertsimasLinda Vahdat Review 14 May 2019 Pages: 535 - 543
Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer Evan N. CohenTamer M. FouadJames M. Reuben Preclinical study 03 May 2019 Pages: 545 - 556
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial Carsten DenkertJan BudcziesGiuseppe Viale Preclinical study 07 May 2019 Pages: 557 - 568
T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer Hitomi MoriMakoto KuboMasafumi Nakamura Preclinical study Open access 08 May 2019 Pages: 569 - 577
Efficacy of a web-based women’s health survivorship care plan for young breast cancer survivors: a randomized controlled trial H. Irene SuShaylyn StarkLoki Natarajan Clinical trial 03 May 2019 Pages: 579 - 589
Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy Hee Jun ChoiJai Min RyuSe Kyung Lee Clinical Trial 07 May 2019 Pages: 591 - 596
Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival B. M. AartsE. G. KlompenhouwerG. Maleux Clinical trial 07 May 2019 Pages: 597 - 605
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO) Christel FontaineVincent RenardHans Wildiers Clinical trial 08 May 2019 Pages: 607 - 615
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy Jennifer Y. ShengAmanda L. BlackfordVered Stearns Clinical trial 11 May 2019 Pages: 617 - 624
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial Noriko SagawaShinji OhnoSeigo Kitano Clinical trial 26 February 2019 Pages: 625 - 630
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study Shinji OhnoHirofumi MukaiYasuo Ohashi Clinical trial 21 May 2019 Pages: 631 - 635
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer Thomas DeckerNorbert MarschnerChristian Lerchenmüller Clinical trial 21 May 2019 Pages: 637 - 647
Adult weight gain accelerates the onset of breast cancer Maria AzradCindy K. BlairWendy Demark-Wahnefried Epidemiology 09 May 2019 Pages: 649 - 656
Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis Mira GoldbergRinku SutradharEileen Rakovitch Epidemiology 10 May 2019 Pages: 657 - 667
Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer Yun Rose LiVicky RoJulia Tchou Epidemiology 13 May 2019 Pages: 669 - 677
Effects of tea consumption and the interactions with lipids on breast cancer survival Jia-Yi ZhangYu-Huang LiaoZe-Fang Ren Epidemiology 16 May 2019 Pages: 679 - 686
Breast cancer risk in relation to plasma metabolites among Hispanic and African American women Hua ZhaoJie ShenWong-Ho Chow Epidemiology 15 February 2019 Pages: 687 - 696
Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women Hua ZhaoJie ShenWong-Ho Chow Correction 01 June 2019 Pages: 697 - 697
Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy Lynn JongenGiuseppe FlorisPatrick Neven Epidemiology 20 May 2019 Pages: 699 - 708
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy Zahraa Al-HilliGrace ChoongJames W. Jakub Brief Report 22 May 2019 Pages: 709 - 716
Microinvasion: could it be sufficient diagnostic criteria for the optimal treatment decision? Darko ZdravkovicNebojsa IvanovicBogdan Crnokrak Letter to the Editor 09 May 2019 Pages: 717 - 717
HER2+ and triple-negative phenotypes in invasive lobular carcinoma might have different specific biological features Kadri Altundag Letter to the Editor 18 May 2019 Pages: 719 - 719
